All In Biotech

Drug Trial Radar · NCT04495296

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 - Claudin18.2 Monoclonal Antibody in the Treatment of Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Aug 13, 2020

Primary completion

Jun 30, 2027

Study completion Sep 30, 2027

Sponsor

Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Jul 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, Phase I trial of TST001. Subjects with locally advanced or metastatic solid tumors will be enrolled. The study will consist of two parts: Part A is dose escalation and dose expansion phase for mono-therapy, and Part B is dose escalation and dose expansion phase for combination therapy in gastric, gastroesophageal junction(G/GEJ) and biliary tract cancer, etc.

Conditions

  • Advanced Cancer

Interventions

  • TST001Drug

    TST001 will be administered by specified doses on specified day

  • OxaliplatinDrug

    Oxaliplatin will be administered by specified doses on specified day

  • CapecitabineDrug

    Capecitabine will be administered by specified doses on specified day

  • PaclitaxelDrug

    Paclitaxel will be administered by specified doses on specified day

  • GemcitabineDrug

    Gemcitabine will be administered by specified doses on specified day

  • CisplatinDrug

    Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day

  • NivolumabDrug

    Nivolumab will be administered by specified doses on specified day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participant Safety as characterized by frequency and severity of adverse events(according to NCI CTCAE 5.0).Time frame: up to 30 days following last dose.
  2. Maximum Tolerated Dose (MTD)Time frame: up to 28 days following first dose
  3. Maximum Tolerated Dose (MTD)Time frame: up to 21days following first dose
  4. Recommended Phase 2 Dose (RP2D)Time frame: up to 30 days following last dose
  5. The incidence and case number of DLT (Dose Limiting Toxicity) in subjects administered with TST001 Q2W in 28 days cycles during observation periodTime frame: up to 28 days following first dose
  6. The incidence and case number of DLT (Dose Limiting Toxicity) in subjects administered with TST001 once every 3 weeks in 21 days cycles during observation periodTime frame: up to 21days following first dose
  7. Safety and Tolerability of TST001 in combination with other therapies, e.g. CAPOX, paclitaxel, GP, nivolumab as characterized by frequency and severity of adverse eventsTime frame: Up to 30 or 90 days following last dose

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Peking University International Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Guangxi, Guangxi, China

  • Hainan Provincial People's Hospital

    Haikou, Hainan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Heibei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • Suzhou Municipal Hospital

    Suzhou, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The First Affiliated Hospital of Jinzhou Medical University

    Jinzhou, Liaoning, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Fudan University Shanghai Cance Center

    Shanghai, Shanghai Municipality, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

  • First Affiliated Hospital of Zhejiang University

    Hangzhou, Zhejiang, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.